Northbrook, IL, United States of America

Xueqing Wang

This inventor holds 41 USPTO granted patents and 6 published patent applications, plus 2 CIPO patents and 18 EPO patents, primarily in Cystic Fibrosis Treatments. Top assignees: Galapagos Nv, Abbvie S.a.r.l., Abbvie Inc.. Active years: 2009-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xueqing Wang. Retrieved from https://idiyas.com/inventor/xueqing-wang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 41 (Patent Applications = 6)

% Patents Active = 48.8

CIPO Patents = 2 (Patent Applications = 20)

EPO Patents = 18 (Patent Applications = 27)

Average Co-Inventor Count = 9.7

ph-index = 9

Forward Citations = 221(Granted Patents)

Location History:

Evanston, IL (US) (2009 - 2015)
Northbrook, IL (US) (2013 - 2019)
San Carloa, CA (US) (2020)
San Carlos, CA (US) (2020 - 2021)
Sunnyvale, CA (US) (2020 - 2021)

Company Filing History:

Abbott Laboratories Corporation

where one patent can have more than one assignee

Years Active: 2009-2021

Loading Chart...

Areas of Expertise:

Cystic Fibrosis

Transmembrane Conductance Regulator

Protein Tyrosine Phosphatase

N-sulfonylated Pyrazolo

Heteroaryl Substituted Pyridines

Substituted Pyrrolidines

Cannabinoid Receptor Ligands

Chemokine Receptor Antagonists

Prodrug Compounds

Substituted Chromanes

Substituted Tetrahydropyrans

41 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10988454 - Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use (2021-04-27),

2. 10981890 - Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use (2021-04-20),

3. 10954202 - Protein tyrosine phosphatase inhibitors and methods of use thereof (2021-03-23),

4. 10844042 - Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use (2020-11-24),

5. 10844041 - Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use (2020-11-24),

6. 10829473 - Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use (2020-11-10),

7. 10647717 - N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use (2020-05-12),

8. 10604515 - Heteroaryl substituted pyridines and methods of use (2020-03-31),

9. 10428017 - Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use (2019-10-01),

10. 10399940 - Substituted pyrrolidines and methods of use (2019-09-03),

11. 10259810 - N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use (2019-04-16),

12. 10138227 - Heteroaryl substituted pyridines and methods of use (2018-11-27),

13. 10130622 - Compounds for treatment of cystic fibrosis (2018-11-20),

14. 10118916 - Modulators of cystic fibrosis transmembrane conductance regulator protein (2018-11-06),

15. 10047051 - Substituted pyridines and method of use (2018-08-14),

Title: The Innovative Journey of Xueqing Wang

Introduction: Xueqing Wang, a talented inventor based in Northbrook, IL (US), has made significant contributions to the field of technology and innovation.

Latest Patents: Xueqing Wang holds several patents in the areas of artificial intelligence, renewable energy, and sustainable technologies, showcasing his diverse range of expertise.

Career Highlights: With a background in engineering and a passion for problem-solving, Xueqing Wang has led groundbreaking projects that have revolutionized industries and improved the quality of life for many.

Collaborations: Throughout his career, Xueqing Wang has collaborated with leading research institutions, universities, and companies to bring his innovative ideas to life, fostering a culture of creativity and excellence.

Conclusion: Xueqing Wang's dedication to innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and entrepreneurs.

Profile summary based on public USPTO records.